A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs IDH 305 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 16 Jan 2018 Planned End Date changed from 1 Apr 2020 to 22 Nov 2020.
- 16 Jan 2018 Status changed to withdrawn prior to enrolment.
- 29 Nov 2016 Status changed from recruiting to suspended.